Unlocking the Potential of C21orf62-AS1: A Potential Drug Target and Biomarker

Target Name: C21orf62-AS1

NCBI ID: G54067

C21orf62-AS1

Other Name(s): C21orf62 antisense RNA 1 | C21orf62-AS1 variant 1 | C21orf49 | C21orf62 antisense RNA 1, transcript variant 1

Unlocking the Potential of C21orf62-AS1: A Potential Drug Target and Biomarker

C21orf62-AS1 is a non-coding RNA molecule located in chromosome 21q13.3. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The discovery of C21orf62-AS1 as a potential drug target has significant implications for the development of new treatments for these debilitating diseases.

C21orf62-AS1: A novel non-coding RNA molecule

C21orf62-AS1 is a small non-coding RNA molecule, typically composed of between 150 and 500 nucleotides. It is expressed in various tissues and cells of the body and is involved in various cellular processes, including gene regulation, DNA replication, and RNA translation.

One of the unique features of C21orf62-AS1 is its potential to interact with various protein molecules. Its C-terminus contains a conserved domain that is known to interact with the protein encoded by the gene SAR1201. This interaction between C21orf62-AS1 and SAR1201 has been demonstrated in various studies, suggesting that C21orf62-AS1 may play a role in the regulation of gene expression.

C21orf62-AS1 as a drug target

The identification of C21orf62-AS1 as a potential drug target has significant implications for the development of new treatments for various diseases. Cancer, neurodegenerative diseases, and autoimmune disorders are some of the most significant diseases that can benefit from new treatments.

C21orf62-AS1 has been shown to be involved in the regulation of various cellular processes that are critical for disease progression. For instance, studies have shown that C21orf62-AS1 is involved in the regulation of cell cycle progression, apoptosis, and angiogenesis, all of which are critical for the development and progression of cancer.

Furthermore, C21orf62-AS1 has been shown to interact with various proteins involved in cancer signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. These interactions suggest that C21orf62-AS1 may play a critical role in the regulation of cancer growth and progression.

C21orf62-AS1 as a biomarker

C21orf62-AS1 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a biomarker has significant implications for the early detection and diagnosis of these diseases.

Studies have shown that C21orf62-AS1 can be used as a biomarker for various types of cancer, including breast, ovarian, and colorectal cancers. Its expression has also been shown to be associated with the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Furthermore, C21orf62-AS1 has been shown to be involved in the regulation of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. Its expression has been shown to be associated with the development of these diseases and may play a critical role in their regulation.

Discussion

The discovery of C21orf62-AS1 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. Its potential as a drug target suggests that it may be a useful target for the development of new therapies for cancer, neurodegenerative diseases, and autoimmune disorders.

Furthermore, its potential as a biomarker for cancer, neurodegenerative diseases, and autoimmune disorders has significant implications for the early detection and diagnosis of these diseases.

Conclusion

In conclusion, C21orf62-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its interaction with various proteins and its potential as a drug and biomarker make it an attractive target for the development of new treatments for these debilitating diseases. Further research is needed to fully understand its role in disease progression and its potential as a drug and biomarker.

Protein Name: C21orf62 Antisense RNA 1

The "C21orf62-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C21orf62-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets